ProMIS Neurosciences, Inc. (PMN)

1.9246 -0.0604 (-3.04%) At close: 04:00PM EDT

ProMIS Neurosciences, Inc.

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada
416 847 6898
https://www.promisneurosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eugene Williams	Co-Founder & Chairman	275k	N/A	1959
Mr. Neil K. Warma M.B.A.	President, Interim CEO, Principal Executive Officer & Director	40k	N/A	1963
Dr. Neil R. Cashman M.D.	Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director	359.66k	N/A	1952
Mr. Gavin T. Malenfant	Chief Operating Officer	416.73k	N/A	1964
Mr. Daniel E. Geffken M.B.A.	Chief Financial Officer	89.03k	N/A	1957
Dr. Johanne Kaplan Ph.D.	Chief Development Officer	260.29k	N/A	1960
Dr. Ernest D. Bush Ph.D.	Head of Pharmacology/Toxicology & Senior Consultant	N/A	N/A	N/A
Dr. David Wishart Ph.D.	Chief Physics Officer	N/A	N/A	N/A
Mr. Dennis Chen Ph.D.	Head of Manufacturing & Senior Consultant	N/A	N/A	N/A
Dr. Larry Douglas Altstiel M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1950

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Corporate governance

ProMIS Neurosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.